Demand for Smart Inhalers Gains Pace to Curb Respiratory Disorders

San Francisco, California, May 02, 2017: TMR Research announces a new report on the global smart inhalers market. The report is based on a solid database of the historical trajectory and deviations exhibited by the global smart inhalers market. The present figures of the market are presented in the report in great detail. Based on a solid analysis of the patterns exhibited by the market, reliable projections are made regarding the future trajectory of the global smart inhalers market. The report is titled ‘Smart Inhalers Market – Global Industry Analysis, Size, Share, Trends, Analysis, Growth, and Forecast 2017 – 2025.’

The global smart inhalers market is a key part of the digitalization movement in the healthcare sector. Smart inhalers are digital respiratory aids that record various aspects of their usage, including the patient’s adherence to the prescribed dosage and the amount being delivered each time. The utilization of modern smart electronics has resulted in smart inhalers that don’t present any inconvenience to the user and can also upload the tracked information to personal electronic devices. Due to the steady incorporation of digital accessories in the healthcare sector, the global smart inhalers market is likely to exhibit steady growth in the coming years.

The rising prevalence of asthma and COPD (chronic obstructive pulmonary disease) has been a prime driver for the global smart inhalers market and is likely to be influential in their rising demand in the coming years. Mounting pollution levels and the increasing adherence to an unhealthy, inactive lifestyle has resulted in a steady rise in the incidence of respiratory conditions, particularly in urban centers. This is likely to drive the demand for smart inhalers due to the rising disposable income of individual consumers. Though the high costs of smart inhalers could restrict their demand in developing regions, developed regions are likely to sustain the demand from the global smart inhalers market in the coming years.

North America is likely to remain the dominant regional market for smart inhalers in the coming years. Allied to its conventional status as the pioneer and early adopter of technological advancements, the strong support from government-supported healthcare agencies has also helped the smart inhalers market in North America.

The increasing demand for home-based care and remote healthcare monitoring is also likely to be a key factor in the growth of the global smart inhalers market in the coming years. As many respiratory conditions don’t require regular physical consultations, doctors as well as patients are turning to digital communication tools to set up remote monitoring facilities. The global smart inhalers market is likely to be a crucial part of this change due to the ease of communicating their recorded data to physicians.

The report also presents a comprehensive analysis of the competitive landscape of the global smart inhalers market. Key smart inhalers market players such as AstraZeneca plc, Teva Pharmaceutical Industries Ltd., Cohero Health LLC, Novartis AG, Boehringer Ingelheim GmbH, and GlaxoSmithKline plc are profiled in the report.

EMBL Collaborates with Enamine for Research on Cancer Treatment

The European Molecular Biology Laboratory (EMBL) and Enamine, have collaborated to develop novel small molecules which works against anti-cancer targets. As per the terms of this collaboration, Enamine is providing medicinal chemistry, library synthesis, and biological services to EMBL for their cause and together they expect to focus on creating new cancer therapeutics and novel modes of action. The collaboration comprises the deployment of medicinal chemists who are Full Time Equivalent (FTE), at Enamine.

 Millions of Compounds Needed to Up Chemical Diversity at Screening Decks

For many years, the EMBL has been working with Enamine to improve the chemical space of their screening library, stated the Head of Chemical Biology Core Facility at EMBL, Joe Lewis. With the realization that above 2 mn collection of compounds can provide quality compounds, there is a need for increasing the chemical diversity of their screening deck. Thus, Enamine was chosen to outsource for their medicinal chemistry discovery program, as the company can help in the field of drug development and chemical biology.

Integration of Chemistry and Biology Service Portfolio

As per David Will, the Head of Medicinal Chemistry at EMBL, the collaboration with Enamine will help their project’s goal of identifying the targets from phenotypic screens, and then synthesizing and triaging patentable preclinical compounds that are new. The access to the world’s largest collection of building blocks at Enamine will go a long way in developing a preclinical compound. The integration of chemistry and biology service portfolio is apt for this kind of research.

“Our collaboration with EMBL illustrates our established engagement with non-profit academic research institutions and disease foundations in their search for strong and committed partners in the most challenging discovery research projects. We look forward to our continued successful work with EMBL”, concluded Michael Bossert, Head Strategic Alliances at Enamine.

RepliCel Receives US Patent for Multi-needle Dermal Injection Devices

RepliCel Life Sciences Inc., a company which specializes in developing cell therapies for orthopedic and aesthetic conditions, received a U.S. patent on April 25, 2017 for its new, multi-needle dermal injection devices. These devices fit as a solution to soaring need for dermal injection technologies capable of bringing high levels of control and precision to any elements injected into the skin.

The patent received from the U.S. Patent and Trademark Office (USPTO) covers technologies designed to allow both repeatable consistency and unparalleled control of product deposition and needle action. The patent also includes the component developed to numb the skin before using injection, with the intention to reduce, if not eliminate, the requirement for local anesthetic prior to aesthetic injection processes.

RepliCel Inches Closer to Launch of RCI-02 with Patent Issued

The first device being designed under the umbrella of this patent is RCI-02, which will be useful in injecting soft tissue fillers, including hyaluronic acid (“HA”). The device is also being designed for injecting RCS-01 skin rejuvenation and RCH-01 hair restoration products. It is expected to be optimized for other injectable such as biologics, drugs, fat grafts, and biologics.

With this patent, the company’s property portfolio has reached a new milestone. The portfolio already included two European patents for RCI-02. Company officials believe that this multi-needle device will be able to deliver unprecedented reproducibility, reliability, and programmability of 3D skin injections, making desired outcomes a much easier thing to attain for both clinicians and less-experienced injection specialists. The prototypes are estimated to get ready by the third quarter of 2017 for initial usability and functional testing by engineers and end users.

Becton, Dickinson & Co Buys C.R. Bard in Cracker US$24 Bn Acquisition

Anyone operating in the medical equipment and technology sector should have an insight into this recently discovered ‘mother of all acquisitions.’ C.R. Bard, a medical device behemoth, has been sold to fellow giant company Becton, Dickinson and Company. Bard has agreed to function under the leadership of Becton Dickinson in a titanic deal of US$24.0 bn or thereabouts.

Companies that supply to hospitals and healthcare centers have attracted eyeballs after the mega deal. The eye-watering acquisition deal kicked Bard’s shares up to almost 20.0% on Monday. Bard will receive an approximately over 25.0% than its share close price of April 21, 2017. This means that Becton Dickinson will bless Bard with a handsome US$317.0 per share, which could be in cash and shares.

Medical Supply and Healthcare Sectors on Merger and Acquisition Spree

Pricing pressure and the need to expand product portfolio are the top reasons that the medical devices sector is witnessing a series of mergers and acquisitions. However, Bard has a different, rather positive, perspective this its acquisition by Becton Dickinson. It will look to leverage the superintendence of Becton Dickinson in infection prevention and medication management to offer worthwhile advantages to patients and customers.

A couple of years back, CareFusion Corp was acquired by Becton Dickinson for exactly half the price of the Becton Dickinson-Bard deal, whereas Abbott Laboratories had acquired St. Jude Medical, Inc. for a billion more than the mega deal price in January 2017.

The scenario of mergers and acquisitions is not merely followed by medical equipment companies, hospitals are also part of the strategy as they share office with larger centralized operations and health systems.